Nymox Pharma To Close Enrollment For NX-1207 Phase 2 Study - Quick Facts

(RTTNews) - Nymox Pharmaceutical Corp. (NYMX) Monday said it is closing enrollment for its Phase 2 study of NX-1207 indicated for the treatment of low risk localized prostate cancer.

The NX03-0040 study involves approximately 150 patients with low grade localized prostate cancer who are randomized to low or high single dose NX-1207. The study assesses the safety and efficacy of a single injection of NX-1207 in eradicating or shrinking the tumors by multiple clinical and laboratory measurements and blinded prostate biopsies at 6 weeks after treatment.

NX-1207 is currently in late stage Phase 3 development in the U.S. for the treatment of benign prostatic hyperplasia. NX-1207 is in Phase development in Europe sponsored by Recordati S.p.A., the company's European licensing partner.